Tag:
liver cancer
Latest Headlines
Latest Headlines
DNA biomarker pinpoints hep B liver cancers
Telomere length in circulating DNA could be a blood-based test for patients who will progress from hepatitis B infection to liver cancer.
ArQule shares jump on positive Phase II liver cancer data
Shares of ArQule ( $ARQL ) spiked more than 20 percent this morning after the biotech announced that its lead drug tivantinib achieved significant results in time-to-progression for patients suffering
Fish oil may counter nerve damage
Fish oil may be on its way to becoming a multitasking miracle drug. Here's the latest: Researchers at Queen Mary, University of London believe that omega-3 fatty acids can protect nerves from...
Low-intensity electromagnetic fields shrink liver cancer tumors
Low-intensity electromagnetic fields much weaker than those produced by a mobile phone helped reduce tumor size and prolong life for a small number of patients with advanced liver cancer, an...
Scientists find molecular chain reaction can lead to cancer
Some new laboratory research bodes potentially well for the crop of Notch inhibitor anti-cancer drugs now under development. In a nutshell: Scientists in the U.S., China and elsewhere have figured
Delcath shares slump after chemo system fails to deliver in PhII cohort
Shares of Delcath Systems ( $DCTH ) slumped 11% this morning after the drug delivery company said its chemosaturation system did not prove effective in a small, mid-stage trial involving a cohort of
SPANosomes deliver siRNA more effectively
If not for a delivery problem, gene-silencing siRNA therapy would be much closer to reality inside the clinic today. But more than a decade after its discovery, siRNA has proven to be difficult to
'Super' stem cell keeps liver cancer going
Researchers in Hong Kong have discovered what makes liver cancer, a scourge of China and southeast Asia, so tough to beat even after the cancer is surgically removed. Turns out, liver cancers are
ASCO confab gives Alnylam, RNAi a shot to shine
Alnylam Pharmaceuticals ( $ALNY ) appears to looking at the annual ASCO confab--the industry's biggest cancer drug meeting--as a key stage to boost the appeal of its gene-silencing or RNAi technology.
Nymox spikes on startling success of animal cancer study
Shares of Nymox spiked dramatically this morning, soaring 59 percent on the news that its experimental therapy for a common type of liver cancer proved highly effective in animal studies. Typically,
